Investor Calendar

Upcoming Events

More events are coming soon.

Presentations

Alector August 2022 Corporate Presentation

AL009 is a Multi-Siglec Inhibitor Engineered to Bind Myeloid Cells That Enhances Innate and Adaptive Immunity to Cancer

Twelve-Month Results from the INFRONT-2 Phase 2 Open-Label Study of latozinemab (AL001) in Frontotemporal Dementia Patients with a C9orf72 Mutation

Update on the INFRONT-2 Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (FTD-GRN)

AL009, a Fusion Protein and Multi-Siglec Inhibitor, Repolarizes Suppressive Myeloid Cells and Potentiates Anticancer Effects

A First-In-Human Study of the Anti-Sortilin Antibody AL101

A Phase 1 Study of AL003 in Healthy Volunteers and Participants With Alzheimer’s Disease

Design of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in FTD-GRN

Past Events

Jun 15, 2022 at
5:00 PM EDT

Goldman Sachs 43rd Annual Global Healthcare Conference

Click here for webcast

May 12, 2022 at
11:20 AM PDT

BofA Securities 2022 Healthcare Conference

Click here for webcast

Mar 28, 2022 at
11:30 AM EDT

Stifel 2022 CNS Days

Click here for webcast

Mar 16, 2022 at
3:20 PM EDT

Barclays Global Healthcare Conference

Click Here for Webcast

Mar 15, 2022 at
8:30 AM EDT

Alector Call to Discuss Data Presented at 2022 Alzheimer’s and Parkinson’s Diseases Conference

Listen to Webcast

Supporting Materials

Twelve-Month Results from the INFRONT-2 Phase 2 Open-Label Study of latozinemab (AL001) in Frontotemporal Dementia Patients with a C9orf72 Mutation 1.3 MB

Mar 8, 2022 at
2:10 PM EST

Cowen 42nd Annual Health Care Conference

Listen to Webcast

Nov 15, 2021 at
2:00 PM EST

Alector presenting at Stifel Conference

Listen to Webcast

Nov 12, 2021 at
4:00 PM EST

Alector Call to Discuss Data Presented at 2021 Clinical Trials on Alzheimer’s Disease Conference and Society for Immunotherapy of Cancer Meeting

Listen to Webcast

Supporting Materials

Update on the INFRONT-2 Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (FTD-GRN) 1.2 MB

Live Teleconference Information

U.S. and Canada - (888) 705-0365
International - (415) 817-9241
Passcode - 2065957

Sep 13, 2021 at
11:45 AM EDT

Morgan Stanley 19th Annual Global Healthcare Conference Fireside Chat

Listen to Webcast

Sep 10, 2021 at
2:00 PM EDT

2021 Wells Fargo Virtual Healthcare Conference

Listen to Webcast

Sep 9, 2021 at
1:25 PM EDT

Citi’s 16th Annual Biopharma Virtual Conference Fireside Chat

Listen to Webcast

Sep 8, 2021 at
11:35 AM EDT

Citi’s 16th Annual Biopharma Virtual Conference: What’s Next for Neurodegenerative Diseases Panel

Listen to Webcast

Investor Calendar

Be the first to hear about our latest discoveries.

Are you sure you want to leave?